Company Profile
Cullinan Therapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- CGEM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
17.21 USD (-1.49%)
Close
Last updated: July 29, 2026
943M USD
Market cap
Why the stock is moving
As of Jul 29, 2026, CGEM closed down 1.49% at $17.21. No new same-company headline was identified in the current news window.
Company overview
T Cell Engager-Focused Biopharma
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing potential first- or best-in-class disease-modifying T cell engagers across cancer and autoimmune diseases. Its strategy centers on using engineered immune-cell redirection to address diseases where existing treatment options remain limited or insufficiently durable.
Lead Oncology Program: CLN-049
CLN-049 is Cullinan’s most visible near-term oncology asset in this news flow. It is a FLT3xCD3 T cell engager being evaluated for acute myeloid leukemia, a disease area where relapsed or refractory patients continue to face poor outcomes. By targeting FLT3 on malignant cells and engaging CD3-positive T cells, the program reflects Cullinan’s broader focus on immune redirection rather than conventional small-molecule or antibody-only oncology approaches.
Potentially Registrational AML Path
The company received positive FDA feedback after an End-of-Phase 1 meeting for CLN-049 and plans to initiate a potentially registrational Phase 2 study in relapsed/refractory AML in the third quarter of 2026. The agreed design includes a short dose-optimization phase followed by seamless progression into a single-arm cohort at the recommended Phase 2 dose. This makes CLN-049 a key catalyst-bearing program for the company.
Cancer and Autoimmune Disease Platform
Although the current regulatory update is focused on AML, Cullinan describes its broader mission as developing disease-modifying T cell engagers in both autoimmune diseases and cancer. That positioning is important: the company is not only pursuing tumor-cell killing, but also applying T cell engager biology more broadly where deep immune-cell depletion or immune modulation could change disease course.
Strategic Position
Cullinan is best understood as a clinical-stage immune-engager company with a near-term oncology catalyst and a broader platform ambition. Its value proposition depends on whether CLN-049 can establish a viable registrational path in relapsed/refractory AML, while the longer-term story rests on extending T cell engager technology across additional cancer and autoimmune indications.
Future catalysts
Cullinan’s catalysts are zipalertinib and CLN-619, which are the main assets investors will use to judge the pipeline. The next oncology updates matter because the company still needs to show its antibody and small-molecule programs can separate from the pack.
Recent news
- 01
- 02
- 03
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Source: Cullinan Therapeutics, Inc.
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cullinan Therapeutics, Inc. (CGEM)?
Cullinan Therapeutics, Inc. (CGEM) most recently closed at 17.21 USD, a -1.49% move versus the previous session.
What is the market cap of Cullinan Therapeutics, Inc. (CGEM)?
Cullinan Therapeutics, Inc. currently has a market capitalization of 943M USD on BioPharmSignal.
What does Cullinan Therapeutics, Inc. do?
T Cell Engager-Focused Biopharma Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing potential first- or best-in-class disease-modifying T cell engagers across cancer and autoimmune diseases. Its strategy centers on using engineered immune-cell redirection to address diseases where existing treatment options remain limited or...
On which exchange is CGEM stock listed?
Cullinan Therapeutics, Inc. (CGEM) is associated with NASDAQ, United States, Biopharma.
What is CLN-049?
Lead Oncology Program: CLN-049 CLN-049 is Cullinan’s most visible near-term oncology asset in this news flow.
Which conditions is Cullinan Therapeutics, Inc. targeting with CLN-049?
Cullinan Therapeutics, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Cullinan Therapeutics, Inc. describe recent progress with CLN-049?
Cullinan’s catalysts are zipalertinib and CLN-619, which are the main assets investors will use to judge the pipeline. The next oncology updates matter because the company still needs to show its antibody and small-molecule programs can separate from the pack.
What is CLN-619?
Cullinan’s catalysts are zipalertinib and CLN-619, which are the main assets investors will use to judge the pipeline.